,96 The phase II ATLANTIC study showed a modest activity of durvalumab (anti-PD-L1 mAb) in a cohort of heavily pretreated patients (at least two previous lines of therapy) with EGFR-mutated NSCLC, with a higher RR in tumors with PD-L1 expression level ≥25%.97 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.